Literature DB >> 25648577

Baseline distribution of participants with depression and impaired quality of life in the Treatment of Preserved Cardiac Function Heart Failure with an Aldosterone Antagonist Trial.

Carine E Hamo1, John F Heitner2, Marc A Pfeffer1, Hae-Young Kim1, Christopher T Kenwood1, Susan F Assmann1, Scott D Solomon1, Robin Boineau1, Jerome L Fleg1, John A Spertus1, Eldrin F Lewis1.   

Abstract

BACKGROUND: Previous studies have demonstrated the psychosocial effect of heart failure in patients with reduced ejection fraction. However, the effects on patients with preserved ejection fraction have not yet been elucidated. This study aimed to determine the baseline characteristics of participants with heart failure with preserved ejection fraction as it relates to impaired quality of life (QOL) and depression, identify predictors of poor QOL and depression, and determine the correlation between QOL and depression. METHODS AND
RESULTS: Among patients enrolled in the Treatment of Preserved Cardiac Function Heart Failure With an Aldosterone Antagonist Trial (TOPCAT), 3400 patients completed the Kansas City Cardiomyopathy Questionnaire, 3395 patients completed European QOL 5D Visual Analog Scale, and 1431 patients in United States and Canada completed the Patient Health Questionnaire-9. The mean summary score on the Kansas City Cardiomyopathy Questionnaire was 54.8, and on European QOL 5D Visual Analog Scale, it was 60.3; 27% of patients had moderate to severe depression. Factors associated with better Kansas City Cardiomyopathy Questionnaire and European QOL 5D Visual Analog Scale via multiple logistic regression analysis were American region, older age, no history of angina pectoris or asthma, no use of hypoglycemic agent, more activity level, and lower New York Heart Association class. Factors associated with depression via multiple logistic regression analysis included younger age, female sex, comorbid angina, chronic obstructive pulmonary disease, use of a hypoglycemic agent, lower activity level, higher New York Heart Association class, and selective serotonin reuptake inhibitor use. There were significant correlations between each of the QOL scores and depression.
CONCLUSIONS: Patients with heart failure with preserved ejection fraction, who were younger had higher New York Heart Association class or comorbid angina pectoris, had lower activity levels, lived in Eastern Europe or were taking hypoglycemic agents, were more likely to have impaired QOL and depression. CLINICAL TRIAL REGISTRATION: URL: http://www.clinicaltrials.gov. Unique identifier: NCT00094302.
© 2015 American Heart Association, Inc.

Entities:  

Keywords:  depression; heart failure; quality of life

Mesh:

Substances:

Year:  2015        PMID: 25648577     DOI: 10.1161/CIRCHEARTFAILURE.114.001838

Source DB:  PubMed          Journal:  Circ Heart Fail        ISSN: 1941-3289            Impact factor:   8.790


  8 in total

Review 1.  Tackling Patient-Reported Outcomes in Atrial Fibrillation and Heart Failure: Identifying Disease-Specific Symptoms?

Authors:  Benjamin A Steinberg; Jonathan P Piccini
Journal:  Cardiol Clin       Date:  2019-05       Impact factor: 2.213

2.  A Randomized Study Examining the Effects of Mild-to-Moderate Group Exercises on Cardiovascular, Physical, and Psychological Well-being in Patients With Heart Failure.

Authors:  Laura S Redwine; Kathleen Wilson; Meredith A Pung; Kelly Chinh; Thomas Rutledge; Paul J Mills; Barbara Smith
Journal:  J Cardiopulm Rehabil Prev       Date:  2019-11       Impact factor: 2.081

Review 3.  Assessing quality-of-life outcomes in cardiovascular clinical research.

Authors:  Daniel B Mark
Journal:  Nat Rev Cardiol       Date:  2016-02-18       Impact factor: 32.419

4.  Beta-blockers and inhibitors of the renin-angiotensin aldosterone system for chronic heart failure with preserved ejection fraction.

Authors:  Nicole Martin; Karthick Manoharan; Ceri Davies; R Thomas Lumbers
Journal:  Cochrane Database Syst Rev       Date:  2021-05-22

Review 5.  Beta-blockers and inhibitors of the renin-angiotensin aldosterone system for chronic heart failure with preserved ejection fraction.

Authors:  Nicole Martin; Karthick Manoharan; James Thomas; Ceri Davies; R Thomas Lumbers
Journal:  Cochrane Database Syst Rev       Date:  2018-06-28

6.  Depressive Symptoms, Cardiac Structure and Function, and Risk of Incident Heart Failure With Preserved Ejection Fraction and Heart Failure With Reduced Ejection Fraction in Late Life.

Authors:  Katja Vu; Brian L Claggett; Jenine E John; Hicham Skali; Scott D Solomon; Thomas H Mosley; Janice E Williams; Anna Kucharska-Newton; Tor Biering-Sørensen; Amil M Shah
Journal:  J Am Heart Assoc       Date:  2021-11-19       Impact factor: 6.106

7.  Prevalence and associations of depression among patients with cardiac diseases in a public health institute in Trinidad and Tobago.

Authors:  Mandreker Bahall
Journal:  BMC Psychiatry       Date:  2019-01-07       Impact factor: 3.630

8.  Comorbidity health pathways in heart failure patients: A sequences-of-regressions analysis using cross-sectional data from 10,575 patients in the Swedish Heart Failure Registry.

Authors:  Claire A Lawson; Ivonne Solis-Trapala; Ulf Dahlstrom; Mamas Mamas; Tiny Jaarsma; Umesh T Kadam; Anna Stromberg
Journal:  PLoS Med       Date:  2018-03-27       Impact factor: 11.069

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.